FY2025 EPS Estimates for Tourmaline Bio Increased by Analyst

Tourmaline Bio, Inc. (NASDAQ:TRML) – Investment analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for shares of Tourmaline Bio in a research note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($3.56) for the year, up from their prior estimate of ($4.01). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.08) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.58) EPS, FY2027 earnings at ($6.32) EPS and FY2028 earnings at ($7.22) EPS.

Tourmaline Bio (NASDAQ:TRML) last announced its earnings results on Thursday, November 7th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.06.

A number of other analysts have also issued reports on the company. BMO Capital Markets began coverage on Tourmaline Bio in a research report on Friday, December 6th. They issued an “outperform” rating and a $50.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of Tourmaline Bio in a report on Wednesday. Guggenheim restated a “buy” rating on shares of Tourmaline Bio in a report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Tourmaline Bio in a research report on Wednesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $54.00.

Tourmaline Bio Stock Performance

Shares of TRML stock opened at $21.81 on Friday. The firm has a market cap of $559.21 million, a P/E ratio of -7.73 and a beta of 2.32. The firm’s 50 day moving average price is $26.02 and its 200-day moving average price is $19.86. Tourmaline Bio has a one year low of $12.12 and a one year high of $48.31.

Institutional Investors Weigh In On Tourmaline Bio

Several large investors have recently bought and sold shares of TRML. Point72 Asset Management L.P. acquired a new position in Tourmaline Bio during the 3rd quarter worth approximately $8,701,000. Blue Owl Capital Holdings LP grew its stake in shares of Tourmaline Bio by 18.5% during the second quarter. Blue Owl Capital Holdings LP now owns 1,715,401 shares of the company’s stock worth $22,060,000 after purchasing an additional 268,000 shares in the last quarter. State Street Corp grew its stake in shares of Tourmaline Bio by 25.6% during the third quarter. State Street Corp now owns 411,980 shares of the company’s stock worth $10,592,000 after purchasing an additional 83,949 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Tourmaline Bio in the second quarter valued at $909,000. Finally, Renaissance Technologies LLC raised its stake in Tourmaline Bio by 184.9% in the second quarter. Renaissance Technologies LLC now owns 100,076 shares of the company’s stock valued at $1,287,000 after buying an additional 64,950 shares in the last quarter. Hedge funds and other institutional investors own 91.89% of the company’s stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.